Factors which affect survival following relapse in neuroblastomas
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers
A novel laboratory model for neuroblastoma research
Establishment of an in vitro model of neuroblastoma initiation using pluripotent stem cell differentiation
Developing a ‘biodegradable paste’ to deliver chemotherapy directly to the brain to treat childhood brain tumours
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
The Little Princess Trust Knowledge Bank of Wilms Tumour
The Little Princess Trust Knowledge Bank of Wilms Tumour
Understanding the biology of relapsed ependymoma brain tumours to help improve treatments
Deciphering the New Molecular Landscape in Paediatric Recurrent Ependymoma: Implications for Molecular Targeted Therapy
Phase II clinical trial: Can a new drug help treat relapsed or refractory (not responding to treatment) ALK+ anaplastic large cell lymphoma?
NIVO-ALCL - Phase II trial of nivolumab for paediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)
Using artificial intelligence to diagnose brain tumours
Moving Artificial Intelligence of Functional Imaging for children’s tumours into a multi-centre environment through a Clinical Decision Support System
Electrotherapy for childhood brain tumours
Electrotherapy for childhood brain tumours